Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Obesity Linked to Protein Involved in Controlling Fatty Acid Uptake

Researchers at the Max Delbrueck Center (MDC) for Molecular Medicine have identified a protein that appears to be involved in controlling the cellular uptake of fatty acids by fat cells, and which may play a role in obesity. Studies in obese mice and overweigh

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Researchers at the Max Delbrueck Center (MDC) for Molecular Medicine have identified a protein that appears to be involved in controlling the cellular uptake of fatty acids by fat cells, and which may play a role in obesity. Studies in obese mice and overweight humans found decreased expression levels of the protein, EHD2, in fat tissue. “We have discovered that overweight people produce less EHD2 than people with normal weight,” said Claudia Matthaeus, PhD, who first observed the phenomenon in the brown adipose tissue of mice during her work at the MDC and who is now a postdoc at the NIH. The researchers reported on their findings in the Proceedings of the National Academy of Sciences (PNAS), in a paper titled, “EHD2-mediated restriction of caveolar dynamics regulates cellular fatty acid uptake.”

Live imaging of mouse cells: The spots moving in and beneath the cell membrane are mostly caveolae. [Claudia Matthaeus, MDC]

Many foods contain lots of fat, and while fatty acids are among the essential nutrients that people need to survive, if we eat more than we can immediately convert into energy, the extra is stored in tissues, to serve as a reserve supply. The quantity of fatty acids that are transported by blood and deposited in tissues is determined by a wide range of factors.

The protein EHD2 has been studied extensively by co-author Oliver Daumke, PhD, professor and group leader at the MDC. The structural biologist has been working to characterize the protein for more than ten years. As a membrane protein, EHD2 resides inside muscle and fat cells. During the inward folding of the cell envelope, small flask-shaped membrane structures called caveolae are formed. These invaginations are particularly abundant in adipocytes, the authors commented. They can either remain on the surface of the cell membrane or they can be pinched off to carry foreign material—potentially including fatty acids—into the cell. It’s a process known as endocytosis. Prior studies have indicated that caveolae may be involved in lipid uptake. The authors wrote, “These results suggest that caveolae are involved in lipid accumulation in adipocytes and may promote FA uptake. However, the molecular mechanisms of caveolae-dependent fat uptake have remained obscure.”

Daumke believes that the EHD2 protein assembles into ring-like structures around the neck of the membrane vessel, which then stymies the pinch-off process. He reasons that if EHD2 is not present as a stabilizer, caveolae can pinch off more frequently and the cell takes up more fat. This is what Matthaeus and her colleagues examined.

The researchers worked with mice in which the EHD2 gene had been switched off. Using an electron microscope, Matthaeus observed that compared with normal mice, in the tissues of the EHD2-knockout mice there were many more caveolae that had become detached from the plasma membrane.

Matthaeus was also able to determine that fatty acid uptake was greater in cells lacking EHD2 and that the lipid droplets, which are intracellular accumulations of fat, were larger in these cells. “We established a link between higher caveolar mobility induced by EHD2 loss and increased cellular fatty acid uptake,” the authors stated. “Concurrently, lipid droplets were enlarged in various tissues of EHD2-lacking mice … The loss of EHD2 on the cellular level led to increased fat deposits on the organismic level, which was particularly evident in older animals.”

The study also indicated a role for EHD2 in human fat metabolism in humans. Matthaeus and a colleague from Leipzig University studied tissue samples from men and women with different body weights. The results showed the fat cells of overweight individuals who had a body mass index of 25 or higher produced less EHD2 than those of people with normal weight. EHD2 expression levels were also lower in two mouse models of obesity than in control mice. “Remarkably, the expression levels of EHD2 were strongly reduced in WAT from obese patients, as well as in WAT of two obese mouse models,” the team stated. It is not clear yet why this is the case. Matthaeus presumes that there is a correlation between frequent membrane pinch-off and the formation of fat depots. “During obesity, we observed that the number of caveolae and their detachment from the membrane get out of sync,” Matthaeus said.

“Our data suggest that EHD2 controls a cell-autonomous, caveolae-dependent fatty acid uptake pathway,” the authors concluded. Notably, obese patients express only low levels of EHD2, implicating a role of EHD2-controlled caveolar dynamics in obesity … We speculate that an imbalance in number, lifetime, and mobility of caveolae may accompany the development and progression of obesity.”

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01How stable is the antibody?

A crucial question often addressed during preclinical development focuses on the in vivo stability of therapeutic antibodies. Increasing the half-life of a therapeutic antibody has several benefits ranging from higher treatment efficacy to increased advantages for the patients who will have a fewer number of therapy sessions and a reduced cost. Given these compelling benefits, following the identification of therapeutic antibodies with the desired specificity, developers usually subject them to a refinement step to increase their stability. This process is often hindered by the lack of reliable experimental tools to predict the half-life of antibodies in patients. The major hurdle of using mouse models to predict antibody stability in the serum lies in the way immunoglobulin proteins are processed by the organism. In mammals, most proteins circulating in the serum undergo constant uptake by endothelial cells and are routed through the endosomes to the lysosomal compartment for degradation. In the endosomes, immunoglobulin G (IgG) proteins are recognized and bound by a transmembrane protein, called the neonatal Fc receptor (FcRn), which mediates their recycling to the plasma membrane and subsequent release back into the serum. As a result, the half-life of IgGs are significantly extended by this mechanism. Since most therapeutic antibodies belong to the IgG class, this recycling system is very relevant for their relative stability in the body. Remarkably, the relative affinity between IgGs and FcRn is extremely disparate between different species, with the mouse receptor showing a much higher affinity than its human counterpart.

Source: www.genengnews.com ↗
02Undruggable or unscreenable?

Another obstacle to discovering new PPI inhibitors is the lack of libraries designed to hunt for them, points out Philippe Roche, PhD, senior scientist at the Integrative Structural and Chemical Biology team at the Cancer Research Center of Marseilles, France. “If you screen PPIs using libraries that were designed for kinases or GPCRs, that’s why you don’t get a lot of good results,” he says. To that end, his group began assembling a library focused on orthosteric inhibitors of PPIs. The result was 2P2Idb, a hand-curated, structural database cataloguing orthosteric inhibitors of PPIs for which the interface had been 3D characterized. From analyzing these known PPI inhibitors, and what structures they had in common, Roche and his colleagues developed a model to predict whether compounds would likely inhibit PPIs. Using this method, 2P2Idb creates an enriched screening library that dramatically increases the hit rate compared to standard libraries. Having proven their success with a small library of 1600 compounds, they are in the process of expanding the library to 10,000 compounds. Once that’s published, “the idea is to make this library available to labs around the world,” Roche says. “We will provide the library free of charge for people to be able to screen PPI targets.”

Source: www.genengnews.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →